Candel Therapeutics (NASDAQ:CADL – Get Rating) and Elevation Oncology (NASDAQ:ELEV – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Profitability
This table compares Candel Therapeutics and Elevation Oncology's net margins, return on equity and return on assets.
Get Candel Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Candel Therapeutics | -29,132.26% | -18.07% | -11.94% |
| Elevation Oncology | N/A | -45.55% | -41.75% |
Earnings and Valuation
This table compares Candel Therapeutics and Elevation Oncology's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Candel Therapeutics | $130,000.00 | 740.08 | -$36.12 million | ($0.81) | -4.11 |
| Elevation Oncology | N/A | N/A | -$32.04 million | ($2.54) | -0.42 |
Insider & Institutional Ownership
22.0% of Candel Therapeutics shares are held by institutional investors. Comparatively, 74.0% of Elevation Oncology shares are held by institutional investors. 44.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 17.0% of Elevation Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings for Candel Therapeutics and Elevation Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Candel Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Elevation Oncology | 0 | 1 | 3 | 0 | 2.75 |
Candel Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 245.35%. Elevation Oncology has a consensus price target of $7.75, suggesting a potential upside of 618.52%. Given Elevation Oncology's higher probable upside, analysts plainly believe Elevation Oncology is more favorable than Candel Therapeutics.
Volatility & Risk
Candel Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
Summary
Candel Therapeutics beats Elevation Oncology on 7 of the 13 factors compared between the two stocks.
About Candel Therapeutics
(Get Rating)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
About Elevation Oncology
(Get Rating)
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.